Literature DB >> 28376511

Anterior segment migration of dexamethasone implant: risk factors, complications, and management.

Ehsan Rahimy1, Rahul N Khurana.   

Abstract

PURPOSE OF REVIEW: To describe the risk factors, clinical course, and complications related to anterior segment migration of a dexamethasone (DEX) intravitreal implant, and review over potential management strategies. RECENT
FINDINGS: Recent reports have demonstrated that migration of a DEX implant into the anterior chamber may occur in patients with higher risk ocular characteristics. Although a relatively rare occurrence, DEX implant migration carries the possibility of inducing potentially vision-threatening corneal endothelial decompensation and edema.
SUMMARY: Any combination of previous pars plana vitrectomy, an open/defective lens capsule, and/or iris defects may increase the risk of DEX implant migration into the anterior chamber. In the setting of a DEX implant that has moved into the anterior segment with corneal edema already present, urgent removal of the implant is warranted to reduce the risk of permanent visual compromise.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28376511     DOI: 10.1097/ICU.0000000000000365

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  11 in total

1.  Steroid-eluting contact lenses for corneal and intraocular inflammation.

Authors:  Lokendrakumar C Bengani; Hidenaga Kobashi; Amy E Ross; Hualei Zhai; Borja Salvador-Culla; Rekha Tulsan; Paraskevi E Kolovou; Sharad K Mittal; Sunil K Chauhan; Daniel S Kohane; Joseph B Ciolino
Journal:  Acta Biomater       Date:  2020-08-16       Impact factor: 8.947

2.  Management of Anterior Chamber Migration of Dexamethasone Intravitreal Implant.

Authors:  Jun Young Ha; Jae Yong Jang; Yong Sok Ji
Journal:  Korean J Ophthalmol       Date:  2017-12

3.  Anterior Chamber Migration of Ozurdex Implants.

Authors:  Özcan Kayıkcıoğlu; Suzan Doğruya; Cansu Sarıgül; Hüseyin Mayalı; Emin Kurt
Journal:  Turk J Ophthalmol       Date:  2020-04-29

4.  Scleral fixation of fluocinolone acetonide implant.

Authors:  Homayoun Tabandeh; Kourous Rezaei
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-12

Review 5.  Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature.

Authors:  Claudio Iovino; Rodolfo Mastropasqua; Marco Lupidi; Daniela Bacherini; Marco Pellegrini; Federico Bernabei; Enrico Borrelli; Riccardo Sacconi; Adriano Carnevali; Rossella D'Aloisio; Alessio Cerquaglia; Lucia Finocchio; Andrea Govetto; Stefano Erba; Giacinto Triolo; Antonio Di Zazzo; Matteo Forlini; Aldo Vagge; Giuseppe Giannaccare
Journal:  Pharmaceutics       Date:  2020-07-26       Impact factor: 6.321

6.  Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®).

Authors:  Daniel H Lee; Clement K Chan
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-30

7.  Dexamethasone Implant Migration through an Iris Coloboma.

Authors:  Yoav Glidai; Shulamit Schwartz; Eyal Cohen
Journal:  Case Rep Ophthalmol       Date:  2020-02-05

8.  Dexamethasone Sustained-Release Intracanalicular Insert for Control of Postoperative Inflammation After Pars Plana Vitrectomy.

Authors:  Ivan J Suñer; Marc C Peden
Journal:  Clin Ophthalmol       Date:  2021-09-17

9.  Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients : Corneal endothelium after dexamethasone implant injection.

Authors:  Hatice Ayhan Güler; Nurgül Örnek; Kemal Örnek; Nesrin Büyüktortop Gökçınar; Tevfik Oğurel; Mehmet Erhan Yumuşak; Zafer Onaran
Journal:  BMC Ophthalmol       Date:  2018-09-04       Impact factor: 2.209

10.  Scleral Fixation of the Fluocinolone Acetonide Implant in Eyes with Severe Iris-Lens Diaphragm Disruption and Recalcitrant CME: The Fluocinolone-Loop-Anchoring Technique (FLAT).

Authors:  Tina R Herold; Raffael Liegl; Susanna Koenig; Ahmed Almarzooqi; Siegfried G Priglinger; Armin Wolf
Journal:  Ophthalmol Ther       Date:  2020-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.